What CICS does

CICS (Cancer Intelligence Care Systems, Inc.; 株式会社CICS) is a Tokyo-based private R&D and medical device company developing accelerator-based Boron Neutron Capture Therapy (BNCT) systems for the treatment of refractory and recurrent cancers. Its flagship product, the CICS-1, is a hospital-deployable neutron source built around an RFQ (Radio Frequency Quadrupole) linear accelerator that generates neutrons via a proton-lithium target reaction, producing low-energy epithermal neutrons (reduced from sub-800 keV source to approximately 10 keV) suitable for BNCT without requiring a nuclear reactor. The therapy exploits the 10B(n,α)7Li nuclear reaction, where boron-10 compounds selectively absorbed by cancer cells are irradiated with neutrons, releasing alpha particles and lithium nuclei that destroy only the targeted cells while sparing surrounding healthy tissue.

The company operates a clinical research and regulatory-approval-centric business model. It conducts Phase I and Phase II clinical trials in partnership with the National Cancer Center Central Hospital (principal site) and Stella Pharma Corporation (developer of the SPM-011 boron drug). CICS is a consolidated subsidiary of Resort Trust Co., Ltd., a diversified Japanese conglomerate, which provides corporate governance and capital backing. Future revenue is expected to derive from sale or leasing of the CICS-1 BNCT system to large Japanese cancer treatment centers, supplemented by clinical research services and potential co-development milestone payments. The company filed its medical device manufacturing and marketing approval application with Japanese health authorities in April 2026, following a Phase II primary endpoint achievement for angiosarcoma in July 2025, marking the transition from clinical development toward commercialization.

Name

CICS

Legal name

株式会社CICS

Website

https://cics.jp

Company type

Private

Founded year

2005

Operating status

Operating

Short description

CICS is a Tokyo-based private medical device company developing the CICS-1, an accelerator-based Boron Neutron Capture Therapy (BNCT) system using an RFQ linear accelerator with a lithium target for hospital-based treatment of refractory cancers. The company, a subsidiary of Resort Trust, filed for Japanese regulatory approval in April 2026.

Ownership category

akta.pro rank

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. BNCT Medical Device System Sales/Leasing: CICS generates revenue through the sale or leasing of its accelerator-based BNCT system (CICS-1) to hospitals and cancer treatment centers. As a medical device requiring regulatory approval, the commercial launch will follow successful approval by Japanese health authorities.
2. Clinical Research Services: CICS conducts Phase I and Phase II clinical trials in collaboration with the National Cancer Center and Stella Pharma, potentially generating revenue through research grants, co-development agreements, and regulatory milestone payments related to the BNCT clinical development program.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

CICS develops and manufactures the CICS-1, an accelerator-based Boron Neutron Capture Therapy (BNCT) system that uses an RFQ (Radio Frequency Quadrupole) linear accelerator with a lithium target to generate low-energy neutrons for cancer treatment. The company provides the medical device along with associated clinical research, operation, and maintenance services, targeting hospital-based deployment of BNCT for refractory cancers such as malignant melanoma and angiosarcoma.

Product overview

CICS (Cancer Intelligence Care Systems) develops BNCT (Boron Neutron Capture Therapy) systems for cancer treatment. Their main product is the CICS-1, an accelerator-based neutron capture therapy device that generates neutrons through an RFQ linear accelerator with a lithium target. The company works with Stella Pharma on the SPM-011 boron drug for use with their system. This represents a city-hospital-based BNCT solution that does not rely on nuclear reactors, marking a significant advancement in cancer treatment technology.

Differentiator

Problem solved

Functional benefit

Products and services

• CICS-1 Accelerator Neutron Capture Treatment Device Accelerator-based BNCT medical device using an RFQ linear accelerator and lithium target to generate low-energy neutrons for cancer treatment. Designed for installation in standard hospital settings without requiring a nuclear reactor. Targets hospitals and cancer treatment centers.
• BNCT (Boron Neutron Capture Therapy) Treatment System A radiation therapy method that selectively destroys cancer cells by injecting boron-10 compounds absorbed specifically by cancer cells, then irradiating with low-energy neutrons from outside the body to cause a nuclear reaction (10B(n,α)7Li) producing alpha rays and lithium nuclei that destroy only cancer cells. Intended for cancer treatment centers and hospitals serving patients with refractory/recurrent cancers.
• BNCT Operation and Maintenance Services Operation and maintenance services for the CICS-1 BNCT system installed at customer hospitals and cancer treatment centers, ensuring safe and sustainable accelerator operation. Targeted at hospitals and cancer centers adopting the CICS-1 device.

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and moderate.

• Stella Pharma Corporation (ステラファーマ株式会社)coreStrategic or Co-development Partner · 7 November 2019CICS and Stella Pharma jointly conduct BNCT clinical trials using CICS-1 (accelerator-based BNCT device with lithium target) and SPM-011 (boron drug, generic name: borofuran (10B)) developed by Stella Pharma. The partnership combines CICS's accelerator neutron source technology with Stella Pharma's boron-10 pharmaceutical compound (using 99%+ enriched 10B from parent company Stella Chemifa). Clinical trials cover malignant melanoma and angiosarcoma. Phase I trials initiated November 2019; Phase II for angiosarcoma initiated November 2022.
• National Cancer Center (国立がん研究センター)coreStrategic or Co-development Partner · 1 January 2014CICS entered into a joint research agreement with the National Cancer Center and installed an accelerator-type neutron capture treatment device in the new outpatient building of the National Cancer Center Central Hospital (completed 2014). The center serves as the primary clinical trial site for BNCT using CICS-1, with Dr. Hiroshi Igaki serving as trial principal investigator (Director, Department of Radiation Oncology).
• NEDO (New Energy and Industrial Technology Development Organization) / 独立行政法人新エネルギー・産業技術総合開発機構moderateStrategic or Co-development PartnerCICS receives NEDO funding support for the development of the Lithium Automatic Regeneration Device, contributing to the sustainability and cost-efficiency of the accelerator-based BNCT system. NEDO is a Japanese government-affiliated R&D funding organization.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Elekta: Elekta is a global radiotherapy and radiosurgery vendor (linear accelerators, Gamma Knife, brachytherapy, software). It is a broad incumbent competing for the same hospital oncology capital and represents the standard-of-care alternative against which any new modality like CICS-1 must justify adoption.
• Accuray: Accuray manufactures CyberKnife and TomoTherapy systems for stereotactic and image-guided radiotherapy. It is a broad radiation-therapy incumbent with comparable hospital sales motions and is relevant for assessing CICS's pricing, positioning, and adoption dynamics.
• Varian Medical Systems (Siemens Healthineers): Varian, now part of Siemens Healthineers, is a global leader in conventional external beam radiotherapy (linacs, treatment planning, proton therapy). It is a broad incumbent that competes for hospital radiotherapy capital budgets and could integrate or compete with novel modalities such as BNCT over time.
• Hitachi: Hitachi has historically been involved in particle therapy and nuclear/medical systems. As a large Japanese conglomerate with deep nuclear engineering expertise, it is a broad incumbent that could enter or expand in accelerator-based BNCT or adjacent particle therapy markets targeted by CICS.

Direct peers

• TAE Life Sciences: TAE Life Sciences is developing accelerator-based BNCT systems (AlphaBeam) for clinical and research use. It is the closest direct competitor to CICS in accelerator-based, hospital-deployable BNCT and competes for the same hospitals, boron-drug partners, and indication pipeline.
• Sumitomo Heavy Industries: Sumitomo Heavy Industries developed the NeuCure cyclotron-based BNCT system, which has been used clinically at Japanese hospitals (including Southern Tohoku BNCT Research Center) and at the National Cancer Center. It is a direct Japanese BNCT peer and the most advanced commercial-stage competitor to CICS.
• Neutron Therapeutics: Neutron Therapeutics produces the nuBeam compact accelerator-based BNCT system designed for in-hospital installation. It directly competes with CICS-1 on the same value proposition of bringing BNCT into standard hospital settings without a nuclear reactor.

Emerging players

• RaySearch Laboratories: RaySearch develops treatment planning and oncology informatics software used across radiotherapy and particle therapy. It is an emerging-adjacent player whose dose-planning software is a potential enabling layer for CICS-1 deployments and whose partnerships with proton/particle vendors provide a useful comp for hospital-side software economics.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CICS